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INTRODUCTION
Capecitabine has the chemical name pentyl [1-(3,4-dihydroxy-
5-methyl-tetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-
pyrimidin-4-yl]aminomethanoate [1]. It is a white to almost-
white solid with a molecular formula of C15H22FN3O6 and 
a molecular weight of 359.3 (Fig. 1). Capecitabine tablets 
contain NLT 93.0% and NMT 105.0% of the labeled amount 
of Capecitabine [2]. Capecitabine is an orally-administered 
chemotherapeutic agent used in the treatment of metastatic 
breast and colorectal cancers. Capecitabine is a prodrug, that 
is enzymatically converted to 5-fluorouracil in the tumor, 
where it inhibits DNA synthesis and slows growth of tumor 
tissue. The activation of Capecitabine follows a pathway with 
three enzymatic steps and two intermediary metabolites, 
5’-deoxy-5-fluorocytidine (5’-DFCR) and 5’-deoxy-5-
fluorouridine (5’-DFUR), to form 5-fluorouracil [3]. The 
final step is the tumor-activated conversion to 5-FU by TP, 
predominantly in malignant cells. This site-specific action 
may result in higher tumor site concentrations and lower 
systemic toxicity than that seen with intravenous use of 5-FU 
[4].
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ABSTRACT
A simple, rapid, accurate and stability indicating RP-HPLC 
method was developed for the determination of Capecitabine 
in pure and tablet dosage form. The mobile phase consisting 
of 0.1% aqcetic acid, methanol and acetonitrile in the ratio of 
35:60:5 v/v. The Inertsil ODS (octadecyl silane), C18, 3V, 250 x 
4.6 mm, 5µm with UV detection 304 nm was used. The retention 
time was found to be 6.4 minutes. The method was statistically 
validated for accuracy, linearity, precision, robustness, specificity 
and range. The method was found linear over the concentration 
range of 50-150 µg/ml. The recovery studies of dosage form 
were also carried out and analyzed; the % relative standard 
deviation (RSD) from recovery studies was found to be within 
limits. The specificity of the method was ascertained by forced 
degradation studies by acid, alkali hydrolysis and oxidation. 
About 35% of drug is degraded in acidic medium and less than 
that in alkaline and oxidative conditions. Due to simplicity, 
rapidity and accuracy of the method, the method will be useful 
for routine analysis and checking purity of capecitabine tablet. 
The method further can be investigated for pharmacokinetic 
and biopharmaceutical analysis.
Keywords: Capecitabine, 5-fluorouracil, metastatic breast, 
colorectal cancer, RP-HPLC, ICH guidelines.
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Capecitabine is administered orally. Absorption is rapid with 
peak plasma levels occurring in about 1.5 hours (compared 
to 2 hours for 5-FU). Food decreases the rate of absorption of 
Capecitabine (60% reduction in peak plasma concentration) 
and AUC by 35%. Less than 60% of Capecitabine and its 
metabolites are bound to plasma protein. The elimination 
half-life of both Capecitabine and 5-FU is about 0.75 hours, 
with more than 70% of the administered dose recovered 
in urine, largely as the alanine metabolite of 5-FU [5]. The 
absolute bioavailability of Capecitabine is 42% with low 
interpatient variability [6].
The usual starting dose is 2,500 mg/m2/day in two divided 
doses, 12 hours apart. One cycle includes two weeks of 
treatment followed by one week without treatment. Cycles 
can be repeated every three weeks [7].
There are many methods which were developed and 
validated for the determination of capecitabine from various 
formulations. In that the HPLC-UV, liquid chromatography 
- tandem mass spectroscopy and automatic pressure 
chemical ionization LC-MS/MS method for determination 
of capecitabine and its metabolites from human plasma, 
using C18 reversed phase column with formic acid solution 
(pH-3) : ethanol (55:45, v/v) as mobile phase, Atlantis dC18 
column under gradient elution respectively which were 
validated according to the FDA guidelines [8-15]. Another 
liquid chromatography- tandem mass spectrometry method 
for determination of capecitabine in dried blood spot, 
separation was done on Phenomenex Gemini C18 column, 
isocratic condition for mobile phase as acetonitrile : 2 mmole 
ammonium formate (80:20, v/v) [16]. Reversed phase method 
was developed for capecitabine determination in bulk and 
pharmaceutical formulations where separation performed 
on Welchrom C18 column with isocratic mobile phase 
containing methanol: acetonitrile: water (50:30:20, v/v) which 
was monitored at 245 nm, method was validated according 
to ICH guidelines [17]. Spectrophotometric methods were 
developed for determination of capecitabine based on their 
oxidation and precipitation reactions, which was monitored 
by measuring absorbance of produced complexes [18]. HPLC 
method was developed for the simultaneous determination 
of capecitabine and its metabolites in mouse plasma, liver, 
human xenograft tumors with electrospray ionization and 
detected by mass spectrometry, this method was cross 
validated in human plasma and human tumor for clinical 
applications [19]. Hence there is need to develop simple, 
accurate, sensitive and selective method for quantification of 
capecitabine.
MATERIALS AND METHODS
Chemicals and reagents
A HPLC grade, acetic acid, acetonitrile, and methanol were 
procured from Merck Labs. Mumbai. Hydrochloric acid, 
sodium hydroxide and hydrogen peroxide were obtained 
from Merck Labs. Mumbai. Distilled water was obtained from 
Milli Q water system in laboratory. Capecitabine reference 
standard was obtained from Glenmark Pharmaceuticals 
Ltd., Sinnar. The marketed formulation of capecitabine was 
procured from local market.
Instrumentation and chromatographic conditions
An isocratic HPLC system of Schimadzu LC2010 UV detector 
having software LC solution was used for chromatographic 
analysis. The chromatographic conditions were optimized 
and these were as shown in Table 1.
Solutions Preparation
Preparation of Mobile Phase
A 0.1 % solution of acetic acid is prepared by dissolving 1 ml 
of glacial acetic acid in sufficient distilled water to produce 
1000 ml. A mixture of 0.1% acetic acid, methanol and 
acetonitrile was prepared in the ratio of 35:60:5, v/v/v and 
degassed by sonication for 30 minutes.
Table 1. Chromatographic conditions
Column Inertsil ODS, 3V, 250 x 4.6 mm, 5 µm, C18
Mobile Phase 0.1% acetic acid, methanol and acetonitrile 35:60:5, v/v/v
Detector (Wavelength) UV 250 nm
Flow rate 1.0 ml/min.
Column temperature 40˚C
Injection volume 10 µl
Run time 10 minute
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Preparation of Standard Stock Solution
A 60 mg of capecitabine pure drug was dissolved in 60 ml of 
mobile phase. It was then sonicated for 5 minutes and made 
up the volume to 100 ml. This solution is then degassed using 
sonicator for 30 minutes (600 µg/ml).
Preparation of Sample
Twenty tablets were weighted. Average weight of tablets 
was calculated. All tablets were crushed to powder 
form. A quantity of powder containing about 60 mg of 
capecitabine was weighed accurately and transferred into 
100 ml volumetric flask. About 70 ml of mobile phase was 
added and sonicated for 15 minutes. It was then cooled to 
room temperature and volume was made up to 100 ml. It 
was then passed through PVDF 0.45µm filter, and used 
thereafter (600 µg/ml). Appropriate aliquot was taken, 
diluted using mobile phase and analyzed by the proposed 
method.
Development of Calibration Curves/ Linearity
Calibration curve for capecitabine standard drug was plotted 
by preparing sample solution by diluting standard solution 
of capecitabine in mobile phase. From this stock solution, 
solutions of 50, 70, 90, 110, 130 and 150 µg/ml concentration 
were prepared. Analysis of these solutions was carried out 
using chromatographic conditions, specified in Table 1.
Assay of Tablet
From the triturate of 20 tablets, an amount equivalent to 60 mg 
of capecitabine was weighed and dissolved in 60 ml of mobile 
phase. It was then sonicated for 10 minutes. The solution 
was filtered through 0.45μ PVDF syringe filter and then final 
volume of the solution was made up to 100 ml with mobile 
phase. Appropriate aliquot was taken, diluted using mobile 
phase and analyzed by the proposed method. Capecitabine 
tablets contain NLT 97.0 % and NMT 102.0 % of the labeled 
amount of capecitabine (C15H22FN3O6) (Table 2).
Method Validation
Methods validation is the process of demonstrating that 
analytical procedures are suitable for their intended use. 
Following aspects were covered during validation of 
developed method as per ICH guidelines [17].
Accuracy
Accuracy expresses the closeness of agreement between 
theoretical and practical value. The average result of mean for 
each level should be within 98 -102% and relative standard 
variation should not be more than 2%. The accuracy study 
Table 2. Assay and precision study of capecitabine tablet
Sr. no. Sample Inter day Intra day
Area Capecitabine  
(%)
Area Capecitabine  
(%)
1. Precision Set 1 9435871 96.9 9440865 97.03
2. Precision Set 2 9478159 98.3 9450325 97.6
3. Precision Set 3 9460601 98.0 9487421 98.6
4. Precision Set 4 9510168 97.6 9450627 97.3
5. Precision Set 5 9457224 97.8 9457324 97.8
6. Precision Set 6 9434868
Average
97.5
97.68
9506984
Average
97.4
97.87
Std. Dev. 0.48 Std. Dev. 0.47
% RSD 0.49 % RSD 0.48
Std. Dev. is standard deviation and % RSD is % relative standard deviation.
Figure 1. Structure of Capecitabine
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was carried out by recovery study. The recovery study 
was carried out by spiking pure capecitabine in marketed 
formulation sample for analysis and determining amount 
of pure drug recovered from same. The results of accuracy 
study are reported in Table 3.
Precision
The precision reflects closeness of agreement between a 
series of results determined by analyzing multiple samples 
of single analyte. According to ICH guidelines, precision can 
be determined by repeatability and intermediate precision 
study. Repeatability expresses degree of obtaining same 
result after analysis of sample over a short period of time. 
Intermediate precision deals with study of within-laboratory 
variations like different days. The results of precision study 
are reported in Table 2.
Specificity
Specificity reflects ability to quantify unequivocally the 
analyte in the presence of components like impurities, 
degradants, and matrix, which may be expected to be present. 
Influence of such interfering components on retention time 
of capecitabine can be assessed by forced degradation studies. 
These were carried out by analysis sample after exposing it to 
0.1 M hydrochloric acid (acidic), 0.1 M sodium hydroxide 
(basic) and 10% hydrogen peroxide (oxidative) solution. The 
results of specificity study are reported in Table 4.
Robustness
Robustness indicates capacity of method to remain unaffected 
due to small but deliberate variations in method parameters 
like flow rate, wavelength of analysis, and or temperature of 
analysis etc. The results of robustness study are reported in 
Table 5.
Linearity and Range
Linearity indicates obtaining test results which were directly 
proportional to the concentration of analyte in the sample 
within range specified. Solutions of 10, 30, 50, 70, 90, 110, 
130, 150, 170, 190 and 210 µg/ml concentration were injected. 
Table 3. Accuracy study of capecitabine tablet
Sr. no. Sample Identity Amt. added in mg Avg. Area Amount Recovered
(mg)
Recovery
(%)
1. Accuracy-50% 30.62 5208950 30.71 101.22
2. Accuracy-100% 61.02 10326070 60.89 100.69
3. Accuracy-150% 87.16 14365781 84.70
Average
98.07
99.99
Std. Dev. 1.69
% RSD 1.69
Amt. is amount, Avg. is average, Std. Dev. is standard deviation and % RSD is % relative standard deviation. For average area (n-=3).
Table 4. Specificity study of capecitabine tablet
Sr. no. Sample Name Area Capecitabine
(%)
1. Control Capecitabine 9866577 101.4
2. 0.1M HCl Degradants 2184640 32.5
Capecitabine 6503440 67.5
3. 0.1M NaOH Degradants 962765 14.6
Capecitabine 8245257 85.4
4. 10% H202 Degradants 408846 7.16
Capecitabine 9072404 93.1
HCl is hydrochloric acid, NaOH is sodium hydroxide, H2O2 is hydrogen peroxide and 0.1 M means 0.1 molar.
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The method was found linear in concentration range of 50 to 
150 µg/ml.
The range is an interval between upper and lower 
concentration of the analyte in the sample where method 
was found linear. Linearity and range study was carried out 
together. The results of linearity and range study are reported 
in Table 6.
System Suitability Testing
System suitability testing is an integral part of many 
analytical procedures. The tests are based on the concept 
that the equipment, electronics, analytical operations and 
samples to be analyzed constitute an integral system that can 
be evaluated as such. System suitability test parameters to be 
established for a procedure depend on the type of procedure 
being validated. The results of system suitability studies are 
reported in Table 7.
RESULT AND DISCUSSION
Capecitabine is an effective anti-cancer agent used in the 
treatment of metastatic breast and colorectal cancers and is 
a prodrug, that is enzymatically converted to 5-fluorouracil. 
The quantitative estimation of capecitabine is possible 
by spectroscopic and chromatographic methods as 
reported. But most of method required buffer solution for 
chromatographic elution [12]. Whereas few method made 
use of gradient elution for same [10-11]. Hence it becomes 
necessary to develop simple chromatographic method 
with isocratic elution, without buffer solution as mobile 
phase component. In this method, it has been achieved by 
developing and validating simple, accurate, precise, sensitive 
and selective method for quantification of capecitabine.
The chromatographic conditions were optimized on trial 
and error method. The wavelength of analysis as 304 nm 
was finalized by analyzing 10 µg/ml solution of capecitabine 
on UV-Visible spectrophotometer. The capecitabine is an 
Table 5. Robustness study of capecitabine tablet
Sr. No. Parameter Area Avg. Capecitabine (%) Std. Dev. % RSD
Set I Set II Set III
1. High flow
(1.1 ml/min)
9128302 9115255 9083072 98.20 0.26 0.26
2. Low flow
(0.9 ml/min)
10821038 10817468 10825702 98.23 0.18 0.19
3. High temp.  
(45˚C)
9714497 9712398 9702982 99.24 0.41 0.41
4. Low temp.  
(35˚C)
9699920 9710011 9693852 99.38 0.66 0.66
Std. Dev. is standard deviation and % RSD is % relative standard deviation. For Avg. of Capecitabine % (n=3).
Table 6. Linearity and range study of capecitabine tablet
Sr. no. Concentration (%) Area
1. 50 5304893
2. 70 83005483
3. 90 9235318
4. 110 10155951
5. 130 11321934
6. 150
Slope
14950420
16227
Intercept 527842
Correlation coefficient 0.99958
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organic entity hence it will have assumed that it will be eluted 
on bonded stationary phases like C8 or C18. Hence, reverse 
phase chromatographic analysis has been proposed. The it 
has been observed that capecitabine was eluted on Inertsil 
ODS, (250 x 4.6 mm, 5 µm) C18 column with good retention 
parameters. The selectin of mobile phase was carried out by 
changing composition of methanol and acetonitrile over wide 
range. But tailing of capecitabine peak was observed. Hence 
0.1% acetic acid solution was used along with methanol 
and acetonitrile. Finally, capecitabine was eluted with good 
retention parameters using 0.1% acetic acid, methanol and 
acetonitrile (5:60:5, v/v), Inertsil ODS, (250 x 4.6 mm, 5 µm) 
C18 column, 1 ml/min flow rate and 304 nm as wavelength 
of analysis. The capecitabine has shown well resolved peak at 
retention time 6.4 minute (Figure 2).
The developed method was applied for quantification of 
capecitabine in marketed formulation. The results of assay 
of capecitabine tables were found to within limits as shown 
in Table 2. The capecitabine tablets were found to contain 
Table 7. System suitability parameters
Parameters Limits (Units)
Tailing factor < 1.25
Therotical plates > 4000
Retention time 6.4 minute
Standard deviation < 1.0 %
% RSD < 2.0 %
Correlation coefficient <0.9977
Table 8. Summary of results
Parameter Acceptance criteria
(Units)
Result obtained
(Units)
Precision % RSD < 1.5% 0.49 %
Accuracy % RSD <2% 1.69 %
Linearity Correlation coefficient >0.9999 0.99958
Robustness: High flow
% RSD < 1.5%
0.26 %
Robustness: Low flow 0.19 %
Robustness: High pH 0.41 %
Robustness: Low pH 0.66 %
Specificity Forced Degradation In 0.1M HCl 32.5% degraded
Range Normally accepted range 70-130 % 90-110 %
NLT 97% and NMT 103% capecitabine. The developed 
method was validated using ICH Q2B guidelines. Nearly all 
validation parameters were studied for developed method. 
The capecitabine was found linear in concentration range of 
50-150 µg/ml with correlation coefficient value, 0.9977. The 
accuracy study was carried out by recovery study whereby 
recovering pure capecitabine from tablet solution. The 
precision study was carried out by analyzing tablet solution 
with change in time of analysis (inter day and intraday). 
The robustness was studied by flow rate and temperature 
of analysis variations. The specificity study was carried out 
by stability study i.e. by forced degradation of capecitabine 
in acidic, alkaline and oxidative conditions. The retention 
time of capecitabine was not changed in presence of its 
degradation products, confirming specificity of method. The 
system suitability parameters like tailing factor, therotical 
plates, retention time etc. were found within limits, 
thereby confirming least influence of instrumental error 
contributing factors. All the results of analysis and validation 
are summarized in Table 8.
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Figure 2. Chromatogram of Standard Drug
Retention time for Capecitabine standard is at 6.4 minute.
Figure 3. Chromatogram for specificity in 0.1M HCl
Peak for Degredant is found at 3.3 minute and for Capecitabine it is at 6.38 minute.
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Figure 5. Chromatogram for specificity in 10% H2O2
Peak for Degredant is found at 2.7 minute and for Capecitabine it is at 6.38 minute.
Figure 4. Chromatogram for specificity in 0.1M NaOH
Peak for Degredant is found at 2.95 minute and for Capecitabine it is at 6.38 minute.
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CONCLUSION
From results of analysis and validation, it can be concluded 
that developed method is simple, accurate, precise, sensitive, 
and selective for quantification of capecitabine from its 
marketed formulations and it can be used for pharmacokinetic 
and biopharmaceutical studies with slight modification in 
optimized chromatographic conditions.
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